Effect of cyclodextrins on topical drug delivery to the eye

Drug Development and Industrial Pharmacy

Volumn 23, Issue 5, 1997, Pages 473-481

  Loftsson, T ^a   Stefansson E ^a  

^a UNIVERSITY OF ICELAND   (Iceland)

Author keywords

[No Author keywords available]

Indexed keywords

ACETAZOLAMIDE; ANANDAMIDE; CYCLODEXTRIN DERIVATIVE; CYCLOSPORIN; DEXAMETHASONE; DEXAMETHASONE ACETATE; DICLOFENAC; ETHOXZOLAMIDE; EYE DROPS; METHAZOLAMIDE; PILOCARPINE;

BIOAVAILABILITY; COMPLEX FORMATION; CONTROLLED STUDY; DRUG SOLUBILITY; EYE; MEMBRANE PERMEABILITY; NONHUMAN; RABBIT; REVIEW; TOPICAL DRUG ADMINISTRATION;

EID: 0343907824     PISSN: 03639045     EISSN: None     Source Type: Journal    
DOI: 10.3109/03639049709148496     Document Type: Review

References (45)

1. G. Thews, E. Mutschler, and P. Vaupel Human Anatomy, Physiology and Pathophysiology, Elsevier, Amsterdam, 1985, p. 619.
2. J. Stjernschantz and M. Astin, in Biopharmaceutics of Ocular Drug Delivery (P. Edman, ed.), CRC Press, Boca Raton, FL, 1993, p. 1.
3. T. Loftsson, E. Stefánsson, H. Friòriksdottir, S. Thórisdóttir, J. K. Kristinsson, and G. Guòmundsdóttir, in Proceedings of the 7th International Cyclodextrins Symposium, Center for Academic Societies Japan, Tokyo, 1994, p. 447.
4. R. E. Records, in Biomedical Foundations of Ophthalmology, Vol. 2, (T. D. Duane and E. A. Jaeger, eds.), Harper & Row, Philadelphia, 1982, p. 1.
5. A. Urtti, J. Ocul. Pharmacol., 10, 349 (1994).
6. A. Urtti and L. Salminen, Surv. Ophthalmol., 37, 435 (1994).
7. C. A. Le Bourlais, L. Treuple-Acar, C. T. Rhodes, P. A. Sado, and R. Leverge, Drug Dev. Ind. Pharm., 21, 19 (1995).
8. Anonymous, Cyclodextrin News, 8, 159 (1994).
9. K. H. Frömming and J. Szejtli, Cyclodextrins in Pharmacy, Kluwer Academic Publishers, Dordrecht, 1994.
10. H. van Doorne, Eur. J. Pharm. Biopharm., 39, 133 (1993).
11. C. T. Rao, H. M. Fales, and J. Pitha, Pharm. Res., 7, 612 (1990).
12. J. Szejtli, Pharm. Tech. Int., 3(2) 15 (1991).
13. J. Szejtli, Pharm. Tech. Int., 3(3) 16 (1991).
14. R. J. Bergeron, in Inclusion Compounds, Vol. 3 (J. L. Attwood, J. E. D. Davis, and D. D. MacNicol, eds.), Academic Press, London, 1984, p. 391.
15. T. Loftsson, H. Friòriksdóttir, E. Stefánsson, S. Thórisdóttir, Ö. Guòmundsson, and T. Sigthórsson, J. Pharm. Pharmacol., 46, 503 (1994).
16. T. Loftsson, H. Friòriksdóttir, S. Thórisdóttir, E. Stefánsson, A. M. Siguròardóttir, Ö. Guòmundsson, and T. Sigthórsson, Eur. J. Pharm. Sci., 1, 175 (1994).
17. M. J. Pérez-Barrales, F. Díaz-Estévez, J. M. Ginés, J. R. Moyano, M. J. Arias, and A. M. Rabasco, Proc. 1st World Meeting APGI/APV, Budapest, May 9-11, 1995, p. 613.
18. D. W. Pate, K. Järvinen, A. Urtti, P. Jarho, and T. Järvinen, Curr. Eye Res., 14, 791 (1995).
19. L. Cheeks, R. L. Kaswan, and K. Green, Curr. Eye Res., 11, 641 (1992).
20. T. Takano, C. Kobayashi, R. M. Alba, and A. Kanai, Nippon Ganka Gakkai Zasshi, 96, 834 (1992).
21. T. Loftsson, H. Frióriksdöttir, S. Thórisdóttir, and E. Stefánsson, Int. J. Pharm., 104, 181 (1994).
22. J. K. Kristinsson, H. Friòriksdóttir, S. Thórisdóttir, A. M. Siguròardóttir, E. Stefánsson, and T. Loftsson, Investig. Ophthalmol. Vis. Sci., 37, 1199 (1996).
23. A. Usayapant, A. H. Karara, and M. M. Narurkar, Pharm. Res., 8, 1495 (1991).
24. O. Reer, T. K. Block, and B. W. Müller, J. Pharm. Sci., 83, 1345 (1994).
25. K. A. Freedman, J. W. Klein, and C. E. Crosson, Curr. Eye Res., 12, 641 (1993).
26. J. Fedder and S. Keipert, Proc. 1st World Meeting APGI/APV, Budapest, May 9-11, 1995, p. 795.
27. K. Järvinen, T. Järvinen, D. O. Thompson, and V. J. Stella, Curr. Eye. Res., 13, 897 (1994).
28. P. Suhonen, T. Järvinen, K. Lehmussaari, T. Reunamäki, and A. Urtti, Pharm. Res., 12, 529 (1995).
29. P. Jahro, A. Urtti, and T. Järvinen, Pharm. Res., 12, 1371 (1995).
30. T. Loftsson, H. Friòriksdóttir, A. M. Siguròardóttir, and H. Ueda, Int. J. Pharm., 110, 169 (1994).
31. T. Hladon and B. Cwiertina, Pharmazie, 49, 497 (1994).
32. É. Fenyvesi, M. Vikmon, J. Szemán, J. Szejtli, P. Ventura, and M. Pasini, in The 7th Cyclodextrins Symposium, Center for Academic Societies Japan, Tokyo, 1994, p. 414.
33. T. Loftsson, Ó. Stefánsdóttir, H. Friòriksdóttir, and Ö. Guòmundsson, Drug Dev. Ind. Pharm., 18, 1477 (1992).
34. S. J. Lehner, B. W. Müller, and J. K. Seydel, J. Pharm. Pharmacol., 46, 186 (1994).
35. J. Dechandt, W. Mehnert, and K. H. Frömming, Eur. J. Pharm. Sci., 2, 179 (1994).
36. T. Jansen, B. Xhonneux, J. Mesens, and M. Borgers, Lens Eye Toxicity Res., 7, 459 (1990).
37. J. C. Javitt, N. B. Javitt, and P. McDonnell, Topical compositions for the eye comprising a beta-cyclodextrin derivative and a carbonic anhydrase inhibitor, International Patent Appl. WO 94/15582, 1994.
38. J. Szejtli, Cyclodextrin Technology, Kluwer Academic Publishers, Dordrecht, 1988, p. 188.
39. T. Loftsson and N. Bodor, in Percutaneous Penetration Enhancers (E. W. Smith and H. I. Maibach, eds.), CRC Press, Boca Rato, FL, 1995, p. 335.
40. M. Tanaka, Y. Iwata, Y. Kouzuki, K. Taniguchi, H. Matsuda, H. Arima, and S. Tsuchiya, J. Pharm. Pharmacol., 47, 897 (1995).
41. A. M. Siguròardóttir and T. Loftsson, Int. J. Pharm., 126, 73 (1995).
42. T. Loftsson, H. Friòriksdóttir, G. Ingvarsdóttir, B. Jónsdóttir, and A. M. Siguròardóttir, Drug Dev. Ind. Pharm., 20, 1699 (1994).
43. T. Loftsson and A. M. Siguròardóttir, Eur. J. Pharm. Sci., 2, 297 (1994).
44. J. Grove, M. P. Quint, and B. Plazonnet, in Minutes of the Fifth International Symposium on Cyclodextrins (D. Duchene, ed.), Editions de Santé, Paris, 1990, p. 479.
45. M. Wilkerson, M. Cyrlin, E. Lippa et al., Arch. Ophthalmol., 111, 1343 (1993).